Brentuximab vedotin and bendamustine: an effective salvage therapy for relapsed or refractory Hodgkin lymphoma patients.

Autor: Uncu Ulu, Bahar, Dal, Mehmet Sinan, Yönal Hindilerden, İpek, Akay, Olga Meltem, Mehtap, Özgür, Büyükkurt, Nurhilal, Hindilerden, Fehmi, Güneş, Ahmet Kürşad, Yiğenoğlu, Tuğçe Nur, Başcı, Semih, Kızıl Çakar, Merih, Yanardağ Açık, Didar, Korkmaz, Serdal, Ulaş, Turgay, Özet, Gülsüm, Ferhanoğlu, Burhan, Nalçacı, Meliha, Altuntaş, Fevzi

Publikováno v: Journal of Chemotherapy (Taylor & Francis Ltd); May2022, Vol. 34 Issue 3, p190-198, 9p

Brentuximab vedotin and bendamustine: an effective salvage therapy for relapsed or refractory Hodgkin lymphoma patients.

Autor: Uncu Ulu B; Department of Hematology and Bone Marrow Transplantation Center, University of Health Sciences, Ankara Dr. Abdurrahman Yurtaslan Oncology Training and Research Hospital, Ankara, Turkey., Dal MS; Department of Hematology and Bone Marrow Transplantation Center, University of Health Sciences, Ankara Dr. Abdurrahman Yurtaslan Oncology Training and Research Hospital, Ankara, Turkey., Yönal Hindilerden İ; Faculty of Medicine, Internal Medicine Department, Division of Hematology, Istanbul University, Istanbul, Turkey., Akay OM; School of Medicine, Department of Hematology, Koç University, İstanbul, Turkey., Mehtap Ö; Faculty of Medicine, Department of Hematology, Kocaeli University, Kocaeli, Turkey., Büyükkurt N; Department of Hematology, Baskent University School of Medicine, Adana Research and Training Hospital, Adana, Turkey., Hindilerden F; University of Health Sciences, Bakirköy Dr. Sadi Konuk Training and Research Hospital Hematology Clinic, Istanbul, Turkey., Güneş AK; Department of Hematology and Bone Marrow Transplantation, Ankara City Hospital, Ankara, Turkey., Yiğenoğlu TN; Department of Hematology and Bone Marrow Transplantation Center, University of Health Sciences, Ankara Dr. Abdurrahman Yurtaslan Oncology Training and Research Hospital, Ankara, Turkey., Başcı S; Department of Hematology and Bone Marrow Transplantation Center, University of Health Sciences, Ankara Dr. Abdurrahman Yurtaslan Oncology Training and Research Hospital, Ankara, Turkey., Kızıl Çakar M; Department of Hematology and Bone Marrow Transplantation Center, University of Health Sciences, Ankara Dr. Abdurrahman Yurtaslan Oncology Training and Research Hospital, Ankara, Turkey., Yanardağ Açık D; Department of Internal Medicine and Hematology, Adana City Education and Research Hospital, Adana, Turkey., Korkmaz S; Department of Hematology, University of Health Sciences, Kayseri Training and Research Hospital, Kayseri, Turkey., Ulaş T; School of Medicine, Department of Internal Medicine, Division of Hematology, Near East University, Nicosia, Cyprus., Özet G; Department of Hematology and Bone Marrow Transplantation, Ankara City Hospital, Ankara, Turkey., Ferhanoğlu B; Department of Hematology and Oncology, VKV American Hospital, Istanbul, Turkey., Nalçacı M; Faculty of Medicine, Internal Medicine Department, Division of Hematology, Istanbul University, Istanbul, Turkey., Altuntaş F; Department of Hematology and Bone Marrow Transplantation Center, University of Health Sciences, Ankara Dr. Abdurrahman Yurtaslan Oncology Training and Research Hospital, Ankara, Turkey.

Publikováno v: Journal of chemotherapy (Florence, Italy) [J Chemother] 2022 May; Vol. 34 (3), pp. 190-198. Date of Electronic Publication: 2021 Sep 13.